A European Medicines Agency (EMA) panel recommended that the one-time gene therapy Itvisma (onasemnogene abeparvovec-brve) be approved for patients with spinal muscular atrophy (SMA) ages 2 and older. The Committee for Medicinal Products for Human Use (CHMP) opinion will be reviewed by the European Commission, which has final say over therapy approvals in Europe. The […] The post SMA treatment Itvisma gets European regulatory panel OK appeared first on SMA News Today .

Source: https://smanewstoday.com/news/sma-treatment-itvisma-gets-european-regulatory-panel-ok/ (Mon, 27 Apr 2026)

Ingested by the SMA platform's daily smanewstoday.com RSS pipeline. Cross-linked to our knowledge graph via the news auto-scoring cron.